Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Performance Tracker

Set Alert for FDA Performance Tracker

Pink Sheet Podcast Special: Why The US Approves Most New Drugs Before The EU

Pink Sheet reporter and editors discuss the impact of a US and EU drug approvals analysis that found the US FDA still clears many novel products first, including most new cell and gene therapies and cancer treatments.

Regional Comparisons Approvals

Cancer, Gene Therapy Top US FDA’s Second Half 2024 User Fee Calendar

Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.

US FDA Performance Tracker Approvals

US FDA Calls ’Em Like Its Advisory Committees See Them

So far this year, when the agency has taken action on NMEs that went before advisory committees, the FDA decision has matched the committee vote.

Advisory Committees Drug Approval Standards

Coming Attractions: Novel Agents In Line For US FDA Decisions By Year-End

Interactive table from the Pink Sheet breaks down the 40 novel drugs and biologics have user fee goal dates before the new year.

Approvals Drug Review

Steady On For US FDA’s Novel Approvals At Mid-Year, But Another 2023 Is Unlikely

US FDA would need to approve 44 novel agents by year-end to match 2023’s big total, but only 40 candidates are known to have user fee goals in the second half of 2024.

US FDA Performance Tracker Approvals

Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications

Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.

Rare Diseases Drug Approval Standards

US FDA’s Dry July? Few Goal Dates Portend Quiet Month For Approvals

Sun’s deuruxolitinib and Novo Nordisk’s insulin icodec stand out as new molecular entities among the small cluster of US FDA user fee goal dates in July.

US FDA Performance Tracker Review Pathway

US FDA’s June Approvals Forecast: Nearly 30 Goal Dates Suggest Hot Start To Summer

June goal dates include RSV and pneumococcal vaccines, two COPD therapies, Rocket and Sarepta gene therapies, and lots of oncology.

US FDA Performance Tracker Drug Review

US FDA’s Novel Approvals Peak Near Year-End, Analysis Of Last Decade Suggests

The Center for Drug Evaluation and Research’s novel approvals concentrated in August, November, and December, while January and June were the slowest months, according to a Pink Sheet analysis of 2014-2023 data.

Approvals US FDA Performance Tracker
See All
UsernamePublicRestriction

Register